Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.
Rokhsar
Cameron
C
Rabhan
Nathan
N
Cohen
Steven R
SR
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D000068800:Etanercept; D016174:Hepacivirus; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D019562:Viral Load
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D008727:Methotrexate